Mitocin (Mitomycin)

Mitocin is employed in the management of bladder cancer, acting on urothelial tumors that have not invaded muscle layers.

• Non‑muscle invasive bladder cancer: reduces tumor recurrence and progression after transurethral resection.
• Carcinoma in situ of bladder: eradicates flat malignant lesions to prevent invasive disease.
• Recurrent superficial bladder tumor: provides intravesical chemotherapy to control disease persistence.

• Mitomycin exerts its antineoplastic effect by acting as a DNA cross‑linking alkylating agent. After intravesical administration, it penetrates urothelial cells and forms covalent bonds between adjacent DNA strands, preventing strand separation during replication. This inhibition of DNA synthesis triggers cell cycle arrest and apoptosis in rapidly dividing cancer cells, while sparing most surrounding normal tissue due to limited systemic absorption.

Mitocin may cause a range of adverse reactions following intravesical administration.

Common Side Effects

• Irritative bladder symptoms: dysuria, urgency, and frequency.
• Hematuria: presence of blood in urine.
• Lower abdominal pain or cramping.
• Nausea or mild vomiting.
• Transient increase in urinary tract infection risk.

Serious or Rare Side Effects

• Severe bladder irritation leading to ulceration.
• Systemic toxicity: bone marrow suppression, anemia, leukopenia.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Renal impairment: elevated creatinine or reduced kidney function.

When using Mitocin, several safety measures and monitoring steps should be observed.

• Patient selection: confirm diagnosis of non‑muscle invasive bladder cancer before treatment.
• Pre‑treatment evaluation: perform cystoscopy and urine cytology to assess disease status.
• Monitoring: check complete blood count and renal function before and after instillation cycles.
• Contraindications: avoid use in patients with active urinary tract infection or severe bladder inflammation.
• Pregnancy and lactation: discontinue in women who are pregnant or breastfeeding; consult obstetric specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitocin can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

• Concurrent systemic chemotherapy agents: may increase cumulative bone marrow toxicity.
• Live vaccines: intravesical mitomycin may impair immune response, increasing infection risk.

Moderate Interactions (Monitor Closely)

• Nephrotoxic drugs (e.g., aminoglycosides): monitor renal function due to potential additive toxicity.
• Anticoagulants: increased risk of hematuria; observe for bleeding.
• CYP450 modulators: may alter systemic exposure if absorption occurs; adjust monitoring.